Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2011 Nov;24(11):1053-8.
doi: 10.1111/j.1432-2277.2011.01315.x. Epub 2011 Aug 29.

Single Shot of Alemtuzumab as Induction Therapy After Kidney Transplantation Is Sufficient

Free article

Single Shot of Alemtuzumab as Induction Therapy After Kidney Transplantation Is Sufficient

Claudia Boesmueller et al. Transpl Int. .
Free article


In an earlier study, we were able to show that Tac monotherapy following 2 × 20 mg alemtuzumab induction is at least as effective as Tac-based triple-drug immunosuppression in cadaveric renal transplantation. We were interested to learn whether 1 × 30 mg of alemtuzumab is as effective as 2 × 20 mg. Patients of the initial study group (group A) received 20 mg alemtuzumab on days 0 and 2, and tac monotherapy from day 2 on. This group acted as control group for the new arm (group C), where patients were given only 1 × 30 mg alemtuzumab on day 0 followed by Tac monotherapy from day 2 on with the same target levels as in the control group. Frequency of rejection at 6 months was 15% in the control group compared to 6% in the study group and 20% at 12 months in group A versus 6% in group C (P = 0.034). Time to rejection was 4.9 months in group A and 0.8 in group C. One-year patient survival was 98.5% in both groups, graft survival 96.9% in group A, and 98.5% in group C. Safety profile was similar in both groups apart from more viral and bacterial infections in group C. Single shot alemtuzumab induction of 30 mg is as effective as 2 × 20 mg in cadaveric renal transplantation.

Comment in

  • Alemtuzumab: right drug, right dose?
    Haynes R, Friend P. Haynes R, et al. Transpl Int. 2011 Nov;24(11):1051-2. doi: 10.1111/j.1432-2277.2011.01341.x. Transpl Int. 2011. PMID: 21981615 No abstract available.

Similar articles

See all similar articles

Cited by 1 article

LinkOut - more resources